In a recent article published on Brownstone.org, author Debbie Lerman discusses the different reactions to the Johnson & Johnson adenovirus COVID-19 vaccine and the BioNTech/Pfizer mRNA vaccine. Lerman highlights the fact that the J&J vaccine was limited to certain individuals due to reported deaths associated with its use, while the Pfizer vaccine, which had over 1,000 reported deaths in the first three months of administration, was not recalled or subject to the same restrictions.
The article begins by citing a report from Stat News, which states that the J&J vaccine was restricted to individuals who cannot take the mRNA vaccines or choose not to be vaccinated with them. This decision was made by the FDA after nine deaths were reported in the first quarter of 2022 among those who received the J&J vaccine. Peter Marks, the FDA's vaccines lead, explained that if there is an alternative vaccine that has similar efficacy but is not associated with deaths, it is deemed safer and more suitable for use.
Lerman then presents a confidential report dated February 28, 2021, which analyzes adverse event reports related to the BioNTech/Pfizer vaccine. The report reveals that there were 1,223 deaths among the total cases analyzed. Lerman clarifies that these cases do not represent the number of people who received the vaccine but rather adverse event cases analyzed by Pfizer on behalf of BioNTech.
The author questions why the Pfizer vaccine, despite having over 1,000 deaths reported in just three months, was not considered a “novel safety concern” or subjected to label changes. Lerman suggests a hypothesis that the Pfizer and Moderna mRNA vaccines were predetermined to be aggressively marketed and remain on the market regardless of any adverse events, including deaths. She speculates that these vaccines were designed by the international biowarfare/biodefense network responsible for managing the COVID-19 pandemic and response.
Lerman concludes by urging readers to explore more about those in charge of the pandemic response and the connection between mRNA vaccines and the biodefense industry.
In this thought-provoking article, Debbie Lerman raises important questions about the differential treatment of COVID-19 vaccines and highlights the discrepancies between the reactions to the J&J vaccine and the Pfizer vaccine. She presents data that challenges the notion of the Pfizer vaccine's superior safety profile compared to the J&J vaccine, questioning the influence of biowarfare networks in shaping vaccine distribution and public health decisions. The article encourages readers to delve deeper into the complexities of the COVID-19 pandemic and the vaccines developed to combat it.
